IP Library › Granted Patent US 10,526,313
Granted Patent B2
US 10,526,313 · App. 15/988,736 · Granted Jan 7, 2020

Rho kinase inhibitor BA-1049 (R) and active metabolites thereof

Inventors: Kenneth M. Rosen (Milton, MA); Matthew D. Abbinanti (Westford, MA); Joerg Ruschel (Cambridge, MA); Lisa Mckerracher (Boston, MA); Lisa Bond Moritz (Burtonsville, MD)
Assignee: BioAxone BioSciences, Inc.
C07D401/12A61K31/4545A61K31/4725A61K31/551A61K45/06C07B59/002C07C55/14C07B2200/05C07B2200/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,526,313
App. No.
15/988,736
Granted
Jan 7, 2020
Kind
B2
Abstract

BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.

Claims (2)

1. A pharmaceutical formulation comprising an adipate salt of a compound of the structure:

2. The pharmaceutical formulation of claim 1 , wherein the compound is deuterated.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Nov 14, 2024
From: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
To: NEURELIS, INC.; AEGIS THERAPEUTICS, LLC
Reel/Frame 069359/0921 →
SECURITY INTEREST Recorded Aug 6, 2021
From: NEURELIS, INC.; AEGIS THERAPEUTICS, LLC
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
Reel/Frame 057111/0242 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2018
From: ROSEN, KENNETH M.; ABBINANTI, MATTHEW D.; RUSCHEL, JOERG; MCKERRACHER, LISA; BOND MORITZ, LISA
To: BIOAXONE BIOSCIENCES, INC.
Reel/Frame 047465/0060 →
Cited By (1)
US 12,661,363